SCHEMBL2161281

SCHEMBL2161281

O=S(=O)(O)c1ccc(N=Nc2c(S(=O)(=O)O)cc3cc(S(=O)(=O)O)cc(O)c3c2O)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT1 Q99873 1/20 0.74
▸ CYP1A2 P05177 3/20 0.67
▸ CYP2C9 P11712 2/20 0.66
▸ MAPK1 P28482 1/20 0.66
▸ DNASE1L3 Q13609 1/20 0.66
▸ PHLPP2 Q6ZVD8 1/20 0.60
▸ ENPP2 Q13822 6/20 0.59
▸ SUMO2 P61956 1/20 0.57
▸ SUMO1 P63165 1/20 0.57
▸ SENP7 Q9BQF6 1/20 0.57
▸ SENP2 Q9HC62 1/20 0.57
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ HTT P42858 1/20 0.52
▸ CD40 P25942 1/20 0.51
▸ CD40LG P29965 1/20 0.51
▸ POLB P06746 1/20 0.50
▸ GRK2 P25098 1/20 0.50
▸ PLEC Q15149 1/20 0.50
▸ CA2 P00918 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3042237 1.00 PRMT1 (0.74) PRMT1CYP1A2CYP2C9MAPK1DNASE1L3
SCHEMBL9273205 0.99 PRMT1 (0.73) PRMT1CYP1A2CYP2C9MAPK1DNASE1L3
SCHEMBL9273197 0.99 PRMT1 (0.73) PRMT1CYP1A2CYP2C9MAPK1DNASE1L3
SCHEMBL29399950 0.99 PRMT1 (0.73) PRMT1CYP1A2CYP2C9MAPK1DNASE1L3
SCHEMBL11791675 0.99 PRMT1 (0.73) PRMT1CYP1A2CYP2C9MAPK1DNASE1L3
SCHEMBL18888951 0.93 PRMT1 (0.65) PRMT1CYP1A2CYP2C9MAPK1DNASE1L3
SCHEMBL5351115 0.92 CYP1A2 (0.71) PRMT1CYP1A2CYP2C9MAPK1DNASE1L3
SCHEMBL5351119 0.92 CYP1A2 (0.71) PRMT1CYP1A2CYP2C9MAPK1DNASE1L3
SCHEMBL24279794 0.91 CYP1A2 (0.70) PRMT1CYP1A2CYP2C9MAPK1DNASE1L3
SCHEMBL5859444 0.91 CYP1A2 (0.70) PRMT1CYP1A2CYP2C9MAPK1DNASE1L3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3366750-B1 STABILIZER AND STABILIZATION METHOD FUJIFILM WAKO PURE CHEMICAL CORP (JP) 2021-07-21 — — EP claimed
US-10961185-B2 Stabilizer and stabilization method FUJIFILM WAKO PURE CHEMICAL CHEMICAL CORPORATION (JP) 2021-03-30 — — US claimed
CN-108138047-B Stabilizer and stabilization method 富士胶片和光纯药株式会社 2021-02-09 — — CN claimed
US-20180290969-A1 STABILIZER AND STABILIZATION METHOD FUJIFILM WAKO PURE CHEMICAL CHEMICAL CORPORATION (JP) 2018-10-11 — — US claimed
EP-3366750-A1 STABILIZER AND STABILIZATION METHOD FUJIFILM Wako Pure Chemical Corporation (JP) 2018-08-29 — — EP claimed
WO-1990015816-A1 SURAMIN TYPE COMPOUNDS AND ANGIOSTATIC STEROIDS TO INHIBIT ANGIOGENESIS THE UPJOHN COMPANY (US) 1990-12-27 — — WO claimed
EP-3948264-A1 NON-BLEACHING COLORIMETRIC AND FLUOROMETRIC ANALYTE DETECTION BY DEGRADATION OF SOLIDS Hach Company (US) 2022-02-09 — — EP disclosed
EP-3366750-B1 STABILIZER AND STABILIZATION METHOD FUJIFILM WAKO PURE CHEMICAL CORP (JP) 2021-07-21 — — EP disclosed
US-10961185-B2 Stabilizer and stabilization method FUJIFILM WAKO PURE CHEMICAL CHEMICAL CORPORATION (JP) 2021-03-30 — — US disclosed
US-10961185-B2 Stabilizer and stabilization method FUJIFILM WAKO PURE CHEMICAL CHEMICAL CORPORATION (JP) 2021-03-30 — — US disclosed
WO-2020198725-A1 NON-BLEACHING COLORIMETRIC AND FLUOROMETRIC ANALYTE DETECTION BY DEGRADATION OF SOLIDS HACH COMPANY (US) 2020-10-01 — — WO disclosed
US-20190202902-A1 ANTIBODY VARIANTS GENENTECH, INC. (US) 2019-07-04 — — US disclosed
US-20180290969-A1 STABILIZER AND STABILIZATION METHOD FUJIFILM WAKO PURE CHEMICAL CHEMICAL CORPORATION (JP) 2018-10-11 — — US disclosed
EP-0789071-A1 METHOD FOR TREATING SURFACE OF SUBSTRATE AND SURFACE TREATMENT COMPOSITION THEREFOR MITSUBISHI CHEMICAL CORPORATION (JP) 1997-08-13 — — EP disclosed
EP-0477195-A1 SURAMIN TYPE COMPOUNDS AND ANGIOSTATIC STEROIDS TO INHIBIT ANGIOGENESIS THE UPJOHN COMPANY (US) 1992-04-01 — — EP disclosed
WO-1990015816-A1 SURAMIN TYPE COMPOUNDS AND ANGIOSTATIC STEROIDS TO INHIBIT ANGIOGENESIS THE UPJOHN COMPANY (US) 1990-12-27 — — WO disclosed
EP-0367873-A1 Hydrocarbon conversion process using a regenerable fluoride-sensitive catalyst UOP (US) 1990-05-16 — — EP disclosed
US-4921946-A REMOVING FLUORINE FROM FEEDSTOCK, CATALYST REGENERATION, IMPROVED DURABILITY UOP (US) 1990-05-01 — — US disclosed
US-4783566-A Hydrocarbon conversion process UOP INC. (US) 1988-11-08 — — US disclosed
US-4361842-A INK JET CANON KABUSHIKI KAISHA (JP) 1982-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180290969-A1 STABILIZER AND STABILIZATION METHOD H1-0, H1-2, H1-4 PRMT1 156/4885CYP1A2 2913/4885CYP2C9 4376/4885
US-10961185-B2 Stabilizer and stabilization method H1-0, H1-2, H1-4 PRMT1 156/4885CYP1A2 2913/4885CYP2C9 4376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback